GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Apures Co Ltd (XKRX:149300) » Definitions » Interest Coverage

Apures Co (XKRX:149300) Interest Coverage : 0 (At Loss) (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Apures Co Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Apures Co's Operating Income for the six months ended in Dec. 2023 was ₩-4,120.3 Mil. Apures Co's Interest Expense for the six months ended in Dec. 2023 was ₩-488.2 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Apures Co's Interest Coverage or its related term are showing as below:


XKRX:149300's Interest Coverage is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 13.21
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Apures Co Interest Coverage Historical Data

The historical data trend for Apures Co's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Apures Co Interest Coverage Chart

Apures Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Apures Co Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Apures Co's Interest Coverage

For the Diagnostics & Research subindustry, Apures Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apures Co's Interest Coverage Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Apures Co's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Apures Co's Interest Coverage falls into.



Apures Co Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Apures Co's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Apures Co's Interest Expense was ₩-488.2 Mil. Its Operating Income was ₩-4,120.3 Mil. And its Long-Term Debt & Capital Lease Obligation was ₩2,632.0 Mil.

Apures Co did not have earnings to cover the interest expense.

Apures Co's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the six months ended in Dec. 2023, Apures Co's Interest Expense was ₩-488.2 Mil. Its Operating Income was ₩-4,120.3 Mil. And its Long-Term Debt & Capital Lease Obligation was ₩2,632.0 Mil.

Apures Co did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Apures Co  (XKRX:149300) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Apures Co Interest Coverage Related Terms

Thank you for viewing the detailed overview of Apures Co's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Apures Co (XKRX:149300) Business Description

Traded in Other Exchanges
N/A
Address
44, Hansan-gil, Cheongbuk-eup, Gyeonggi-do, Pyeongtaek-si, KOR, 17792
Apures Co Ltd is a South Korea based company engaged in the development of transgenic animals to support bio heterogeneous long-term commercialization and new drug efficacy research. It has focused its research capabilities on developing transgenic mini pigs based on gene editing technology and somatic cell nuclear transfer technology.

Apures Co (XKRX:149300) Headlines

No Headlines